GHK-Cu Guide & Protocols

GHK-Cu's research notes page covers the science: what it is, what's been studied in skin and wound healing, and the fact that the injectable and systemic research is a much thinner, mostly animal-model body of work compared to the decades of topical and cosmetic data. This page picks up where that one leaves off, with the part people actually come looking for once they've decided to research it by injection: how it gets reconstituted and dosed, how a cycle is commonly structured, what it's stacked with, and how injectable use stacks up against the topical serums GHK-Cu is better known for.

Vial size isn't part of what follows, since the amount of bacteriostatic water you add sets your concentration either way. Our reconstitution calculator handles that math for whatever vial and target dose you're working with.

What it is

GHK-Cu is a naturally occurring copper peptide, three amino acids bound to a copper ion, that the body produces on its own and that declines with age. It's sold as a research chemical in powder form, and separately, under names like Copper Tripeptide-1, as an ingredient in cosmetic serums and creams. Those are two different products with two different evidence bases, not one compound with two names for the same thing. See the GHK-Cu research notes for the mechanism and the research areas in full before reading the dosing below.

What people use it for

The topical side, serums and creams, is where GHK-Cu built its reputation, and that's the version with real human data behind it from dermatology research. The injectable side is a newer conversation, and it's mostly people who are already researching skin, collagen, and tissue repair by injection for other compounds, BPC-157 and TB-500 especially, and adding GHK-Cu to that research protocol rather than arriving at GHK-Cu on its own. A smaller slice of interest comes from the longevity and healthy-aging side, usually paired with Epithalon.

If skin support is the whole goal and injection isn't something you're interested in, the topical route has more evidence behind it. The comparison further down walks through that trade-off directly.

Formulations

Research-grade GHK-Cu ships as a lyophilized (freeze-dried) powder that needs reconstitution before injection. Vendors most commonly sell 50 mg and 100 mg vials, with smaller 5 mg and 10 mg vials available from a handful of sources. It also shows up pre-blended with other research peptides, most often BPC-157 and TB-500 in the GLOW blend, and BPC-157, TB-500, and KPV in the four-peptide KLOW blend. Treat a blend as separate compounds sharing one vial rather than a distinct formulation, and confirm the milligram amount of each component before comparing its price against a single-compound vial.

Dosing protocols

There's no clinical trial establishing an injection dose for GHK-Cu in people. What circulates is a range that vendors and research forums converged on, drawing on the animal-model doses scaled up in size and on general copper-peptide handling, not on a human trial that set the number.

See the GHK-Cu research notes for what the actual evidence looks like before reading the dosing itself.

Standard protocol

The most commonly referenced pattern. Daily dose: 1 to 2 mg. Route: subcutaneous injection. Duration: run continuously, or in extended stretches of 4 to 8 weeks with a short break between, rather than the fixed short course some other research peptides use.

Higher-range variant

A less common variant, referenced mainly in longevity-focused forums. Daily dose: up to 5 mg. Route: subcutaneous injection. Same continuous-or-extended-stretch structure as above.

Course total, for planning your vial purchase: at 1 to 2 mg daily, a 30-day month works out to 30 to 60 mg total. That means a single 50 mg vial covers roughly three to seven weeks depending where in that range you land, and a 100 mg vial roughly seven weeks to three months. At the higher-range variant of up to 5 mg daily, a 50 mg vial covers 10 days at most. Compare vendors on price per milligram against whichever total you're actually planning to use, not against the price of one vial.

Cycling guidelines

Unlike some research peptides that run on a short, defined course, the convention for GHK-Cu leans toward continuous or near-continuous use, mirroring the logic of a topical routine carried over into an injectable one, with a short break every 4 to 8 weeks referenced more often than not. That's a convention drawn from how people talk about running it, not a cycle length anyone traces to a specific source.

Signs a cycle is commonly stopped early:

• Persistent injection-site reaction beyond mild, brief redness
• Any metallic taste, nausea, or symptom that could plausibly relate to copper intake specifically
• Any new symptom you can't otherwise explain

Stacking

Most popular stack: GHK-Cu with BPC-157 and TB-500.

Rationale: all three sit in the tissue repair and skin research interest, with different roles suggested in the literature, collagen and repair signaling for GHK-Cu, gut and general tissue repair research for BPC-157, and tissue remodeling research for TB-500. This is the combination sold pre-mixed as the GLOW blend, and with KPV added, as KLOW.

Protocol as run: when bought as GLOW or KLOW, all components are reconstituted and dosed together in the blend's fixed ratio. When bought separately, GHK-Cu is more often run on its own continuous schedule while BPC-157 and TB-500 follow their own shorter defined courses.

Why it's paired: the three get sold together constantly because they answer to the same skin-and-repair research interest, not because there's a clinical trial on the combination. Treat a blend's convenience as a reason to check the per-component math, not as evidence the combination itself has been studied.

Lighter stacks: GHK-Cu alongside Epithalon shows up in the general longevity and healthy-aging research interest, run as two separate schedules in the same general period rather than one combined protocol.

Considerations: running GHK-Cu alongside other copper-containing supplements or a multivitamin with copper adds up in ways that are easy to lose track of, since copper research generally treats total intake as the relevant number, not any one source in isolation.

Expected results timeline

Early days: nothing acute is expected. Anything noticed in the first week or two is more likely the injection routine itself than the peptide.

During a cycle: this is where skin texture and healing-related reports cluster in forum and vendor anecdote, self-reported rather than measured.

Cumulative (across months of use): any collagen or skin-related change would show up here at the earliest, and it's the piece with the least direct human evidence behind it for the injectable route specifically, since the strongest skin data comes from topical studies, not injection.

What to expect realistically: a compound with a large topical evidence base and a much thinner injectable one. Skin and healing-related self-reports are the most commonly discussed signal for the injectable route. A measurable change without before-and-after photos or lab testing isn't a reasonable expectation to hold yourself to.

Administration technique

1. The lyophilized powder is reconstituted with bacteriostatic water, at a concentration set by the reconstitution calculator for the target dose.
2. The solution is swirled gently to dissolve rather than shaken, since agitation can degrade the peptide.
3. The calculated volume is drawn into an insulin syringe.
4. A subcutaneous site is chosen, commonly the abdomen, with sites rotated day to day to reduce local irritation.
5. The skin is pinched and the injection given at roughly a 45-degree angle, held for a few seconds before withdrawal.
6. Each injection is commonly logged by date, dose, and site, which matters more here than on a short fixed course, since continuous use runs for months rather than days.

Side effects and safety

Common: mild redness, stinging, or irritation at the injection site, reported somewhat more often than with non-metal peptides, which tracks with copper complexes generally being more locally irritating.

Less common: headache, and a metallic taste some people report after injection.

What we don't know: there is no completed human safety data for injectable GHK-Cu specifically. What exists is decades of topical and cosmetic safety data, which doesn't transfer directly to a systemic route, plus animal-model work on the injectable side. Treat systemic safety as an open question, not one the topical track record has already answered.

Contraindications: anyone with a copper metabolism disorder, Wilson's disease being the one specifically to know about, should avoid supplemental copper in any injectable form. Pregnancy, breastfeeding, and use in minors all have no data behind them and should be avoided.

Drug interactions: none have been formally characterized for the injectable route. That's an absence of data, not evidence of safety, and it's worth factoring in if you're already taking a copper-containing supplement or multivitamin.

GHK-Cu injection vs. topical GHK-Cu

If you're weighing whether to research GHK-Cu by injection at all, topical use is the actual alternative, not a different peptide. Both deliver the same compound, and the honest comparison is about the evidence base and the route, not about which one "works better."

Choose injection if: your research interest is the systemic collagen, repair, or longevity angle, and you're comfortable with a much thinner human evidence base than the topical route has.

Choose topical if: skin texture and localized aging support is the actual goal, since that's the use case with real human research behind it and a much simpler risk profile.

Using both: some people run a topical serum for skin alongside an injectable protocol aimed at the broader repair or longevity research interest. That's two separate use cases layered together, not one protocol doing double duty.

Storage and handling

Lyophilized powder: refrigerate at 2 to 8°C, protected from light. Stable up to 24 months under proper storage, though lot-specific stability should come from the vendor's certificate of analysis rather than a general rule.

Reconstituted solution: refrigerate, and use within about 4 weeks once water has been added. Copper-peptide complexes in particular are sensitive to pH shifts and oxidation once in solution, so a solution that's changed color or gone cloudy is worth discarding even inside that window.

Signs of degradation:

• Cloudiness or visible particles in a solution that was previously clear
• A shift toward a darker or duller color than the solution had when freshly mixed
• A course that produces none of the previously noticed subjective effects, though this is a soft signal at best

FAQ

Is GHK-Cu injection or topical use better studied? Topical, by a wide margin. The injectable route is mostly animal-model research with no completed human trials.

How long is a typical injectable cycle? Continuous or near-continuous, most commonly referenced in 4 to 8 week stretches with a short break, rather than a fixed short course.

What's the most common daily dose people reference? 1 to 2 mg subcutaneously, with up to 5 mg referenced less often, mainly in longevity-focused forums.

Can I use a topical serum and an injectable protocol together? People do, treating them as two separate use cases rather than one combined protocol.

Is there a safety concern specific to GHK-Cu? Copper metabolism disorders, Wilson's disease specifically, are the clearest contraindication, since this is a copper-delivering compound.

How is it stored? Refrigerated as a powder, refrigerated and used within about 4 weeks once reconstituted.

What's it commonly stacked with? BPC-157 and TB-500, often bought pre-blended as GLOW or KLOW, and separately, Epithalon for the longevity angle.

Bottom line

Key dosing takeaways:

• 1 to 2 mg daily, subcutaneous, run continuously or in extended stretches with short breaks, is the pattern people most commonly reference
• That range is community convention drawn from animal-model dosing and general practice, not a number any human trial established
• The injectable route has a much thinner human evidence base than topical GHK-Cu; see the comparison above before deciding which one actually fits your research interest

Best practices:

• Comparing vendors by monthly total in milligrams, not by single vial price, is where the real cost differences show up over a continuous protocol
• Logging each injection matters more here than on a short course, since continuous use runs for months
• Checking your total copper intake, supplements included, is worth doing before adding an injectable copper peptide on top

Works best for people who:

• Are already researching BPC-157, TB-500, or Epithalon and want to add GHK-Cu to that same repair or longevity interest
• Are comfortable with a much thinner human evidence base than the topical route has for this specific compound
• Want the systemic angle rather than a localized skin effect, and understand that trade-off going in